NRD
NVCR icon

Nebula Research & Development’s NovoCure NVCR Stock Holding History

Nebula Research & Development’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-21,042
Closed -$360K – 1104
2024
Q2 		$360K Buy
+21,042
New +$370K 0.06% 532

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nebula Research & Development's NVCR Position: Q3 2024 in Review

Nebula Research & Development sold out of NovoCure (NVCR) in Q3 2024, closing a stake of 21,042 shares — an estimated $360K sold.

Nebula Research & Development first reported a position in NVCR in Q2 2024 and held it in 1 quarter. The position peaked at $360K in Q2 2024. 224 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

  • Nebula Research & Development reported no remaining NovoCure position as of Q3 2024 after selling out during the quarter.
  • Nebula Research & Development sold 21,042 NovoCure shares in Q3 2024, an estimated $360K.
  • Nebula Research & Development first reported a position in NovoCure in Q2 2024 and held it in 1 quarter.
  • Nebula Research & Development's NovoCure position peaked at $360K in Q2 2024.
  • 224 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on Nebula Research & Development's 13F filing for Q3 2024, filed 14 Nov 2024.